Skip to content
Companies

Avivomed

Implantable nerve stimulation for obstructive sleep apnea

Raised to date

$5M

of $12M offered across 1 Form D filing

Still open
$7M
Investors
7
Last filed
Apr 21, 2026

About

Avivomed is a Minnesota-based medical device company developing next-generation, minimally invasive neuromodulation therapies for obstructive sleep apnea (OSA). Its implantable systems stimulate nerves involved in maintaining an open upper airway during sleep, targeting the large share of OSA patients who cannot tolerate CPAP. The company was founded in 2021 and operates within the NuXcel innovation ecosystem. It is backed by F-Prime, Hatteras Venture Partners, Norwest, and Treo Ventures.

A minimally invasive implantable neurostimulation approach positioned as an alternative for the up to 50% of obstructive sleep apnea patients who cannot tolerate CPAP, developed by a team with prior experience building implantable neuromodulation systems for hearing and sensory restoration.

Funding

  • DebtFiled Apr 21, 2026Form D
    $5M/ $12M

Product

Minimally invasive neuromodulation system for obstructive sleep apnea

Implantable medical device

An implantable neurostimulation system in development that delivers targeted nerve stimulation to help keep the upper airway open during sleep, treating obstructive sleep apnea without a mask or external airflow device.

  • Minimally invasive implantable design
  • Neuromodulation-based airway therapy delivered during sleep
  • Aimed at CPAP-intolerant obstructive sleep apnea patients

Built for

Adults diagnosed with obstructive sleep apnea, particularly those who cannot tolerate CPAP therapy, reached through sleep physicians and implanting surgeons

People on file